Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20042406 | 0.91 | MMP2 (0.84) | MMP2PTGS2PTGS1CYP2C9CA1 | |
| SCHEMBL6906476 | 0.89 | MMP2 (0.70) | MMP2PTGS2PTGS1CYP2C9CHRNA7 | |
| SCHEMBL18180816 | 0.89 | CYP2C9 (0.77) | MMP2PTGS2PTGS1CYP2C9CA1 | |
| SCHEMBL27605220 | 0.87 | PTGS2 (0.80) | MMP2PTGS2PTGS1CYP2C9CA1 | |
| SCHEMBL8119339 | 0.87 | PTGS2 (0.88) | MMP2PTGS2PTGS1CYP2C9CHRNA7 | |
| SCHEMBL20042410 | 0.87 | MMP2 (0.67) | MMP2PTGS2CYP2C9CA1CA2 | |
| SCHEMBL20042427 | 0.86 | PTGS2 (0.79) | MMP2PTGS2PTGS1CYP2C9CHRNA7 | |
| SCHEMBL20044910 | 0.86 | PTGS2 (0.70) | MMP2PTGS2PTGS1CYP2C9CHRNA7 | |
| SCHEMBL6309469 | 0.85 | PTGS2 (0.58) | MMP2PTGS2PTGS1CYP2C9CHRNA7 | |
| SCHEMBL18180791 | 0.84 | PTGS2 (0.69) | MMP2PTGS2PTGS1CYP2C9CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11202773-B2 | Locally bioavailable drugs | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-12-21 | — | — | US | disclosed |
| US-20180098965-A1 | LOCALLY BIOAVAILABLE DRUGS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180098965-A1 | LOCALLY BIOAVAILABLE DRUGS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098965-A1 | LOCALLY BIOAVAILABLE DRUGS | ABCG2, FABP1, FABP2 | MMP2 1054/4885PTGS2 3366/4885PTGS1 3087/4885 |
| US-11202773-B2 | Locally bioavailable drugs | ABCG2, FABP1, FABP2 | MMP2 1054/4885PTGS2 3366/4885PTGS1 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.